FDA Updates Public Information About Known Risk of Lymphoma From Breast Implants

March 23, 2018 – On March 21, the U.S. Food and Drug Administration (FDA) issued updated information about its understanding of breast implant–associated anaplastic large cell lymphoma (ALCL). The agency is providing an updated number of medical device reports (ie, adverse event reports) and medical literature estimates regarding risk reviewed by the agency since the last public update in March 2017. It reported that it was aware of 414 total cases of … (leggi tutto)